KLK4 and lung carcinoma: Activation peptide of the coagulation factor XIII (AP-F13A1) and plasma kallikrein (fragment) were identified to be novel biomarkers for the screening of CRC and lung cancer, respectively (Chee et al., 2008; Peltier et al., 2018).